Richard S. Finn, MD

Articles

Dr. Finn on Biomarkers of Response in HCC

March 12th 2020

Richard S. Finn, MD, discusses biomarkers of response to immunotherapy in hepatocellular carcinoma.

Dr. Finn on the Rationale for the Phase III KEYNOTE-240 Trial in HCC

September 25th 2019

Richard S. Finn, MD, professor of clinical medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles (UCLA), and Director of the Signal Transduction and Therapeutics Program at the Jonsson Comprehensive Cancer Center at UCLA, discusses the rationale for the phase III KEYNOTE-240 trial in hepatocellular carcinoma (HCC).

Dr. Finn Discusses Sequencing Therapy for HCC

August 7th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

Dr. Finn Recaps Second-Line Advancements in HCC

June 22nd 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

Dr. Finn Discusses the Pooled Analysis of REACH and REACH-2 in HCC

June 20th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the pooled analysis of the REACH and REACH-2 studies in patients with hepatocellular carcinoma.

Dr. Finn on the FDA Approval of Frontline Abemaciclib in HR+/HER2- Breast Cancer

February 27th 2018

Richard S. Finn, an associate professor of medicine at the Geffen School of Medicine at the University of California, Los Angeles, discusses the FDA approval of abemaciclib (Verzenio) for use in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer.

Dr. Finn on the Revolution of CDK4/6 Inhibition in HR+ Breast Cancer

November 10th 2017

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses the significant advances with CDK4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer

October 11th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.

Dr. Finn on Recent Advances in the Treatment of Liver Cancer

September 20th 2016

Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses both recent advances in the treatment of patients with liver cancer, as well as the future role that immunotherapy stands to have in this field.

Dr. Finn on Finding a Biomarker for Patients With HCC

September 10th 2016

Richard S. Finn, MD, an associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the challenges with determing a biomarker for patients with hepatocellular carcinoma (HCC) in an interview during the 10th Annual Conference of the International Liver Cancer Association (ILCA) in Vancouver, Canada. Finn is the current ILCA president.

Dr. Finn on Regorafenib for the Treatment of Patients With HCC

July 25th 2016

Richard Finn, assistant professor of Medicine at the Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology at UCLA Jonsson Comprehensive Cancer Center, discusses regorafenib (Stivarga) for the treatment of patients with hepatocelluar carcinoma (HCC).

Dr. Finn Discusses Palbociclib for Patients With Advanced Breast Cancer

February 10th 2015

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses findings from a phase II PALOMA-1/TRIO-18 study that examined palbociclib in combination with letrozole as a first-line treatment with ER-positive, HER2-negative, advanced breast cancer.

Dr. Finn on the Potential of CDK Inhibition

February 13th 2014

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the potential of CDK inhibition in breast cancer and other malignancies.

Dr. Finn on AMG900 in Breast Cancer

December 2nd 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses using AMG900 to treat breast cancer.

Dr. Finn Discusses Research in Triple-Negative Breast Cancer

November 19th 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).

Dr. Finn on the Phase III Trial of Palbociclib for Breast Cancer

September 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the design of a phase III trial looking at palbociclib for the treatment of patients with estrogen receptor-positive metastatic breast cancer.

Dr. Finn on New CDK 4/6 Inhibitors for Breast Cancer

August 19th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses new CDK 4/6 inhibitors for the treatment of breast cancer.

Dr. Finn on the Future of Palbociclib in Breast Cancer

June 6th 2013

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the potential impact of the cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer.

Dr. Richard Finn on the Rationale for Targeting CDK4/6

March 4th 2013

Richard Finn, MD, from Jonsson Comprehensive Cancer Center, discusses the rationale for targeting cyclin-dependent kinases 4 and 6 with the novel agent PD 0332991 in breast cancer.

Dr. Finn on PD 0332991 Plus Letrozole in Breast Cancer

December 5th 2012

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes results from a phase II study that examined PD 0332991 in combination with letrozole for women with metastatic ER-positive breast cancer.